Pharmaceutical Information |
Drug Name |
Risdiplam |
Drug ID |
BADD_D02592 |
Description |
Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).[L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription. This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy [onasemnogene abeparvovec], whereas risdiplam offers the ease of oral bioavailability.[L15351,A216871]
Risdiplam was approved by the FDA in August 2020 for use in patients 2 months of age or older in the treatment of spinal muscular atrophy (SMA).[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless of severity or type. |
Indications and Usage |
Risdiplam is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.[L15336] |
Marketing Status |
approved; investigational |
ATC Code |
M09AX10 |
DrugBank ID |
DB15305
|
KEGG ID |
D11406
|
MeSH ID |
C000629884
|
PubChem ID |
118513932
|
TTD Drug ID |
D0N5MH
|
NDC Product Code |
50242-175 |
UNII |
76RS4S2ET1
|
Synonyms |
Risdiplam | 7-(4,7-Diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-4H-pyrido(1,2-a)pyrimidin-4-one |
|
Chemical Information |
Molecular Formula |
C22H23N7O |
CAS Registry Number |
1825352-65-5 |
SMILES |
CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6 |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|